

**SARS Antibody (N-term) Blocking peptide**  
Synthetic peptide  
Catalog # BP11092a**Specification**

---

**SARS Antibody (N-term) Blocking peptide - Product Information**Primary Accession [P49591](#)**SARS Antibody (N-term) Blocking peptide - Additional Information**

Gene ID 6301

**Other Names**

Serine--tRNA ligase, cytoplasmic, Seryl-tRNA synthetase, SerRS, Seryl-tRNA(Ser/Sec) synthetase, SARS, SERS

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SARS Antibody (N-term) Blocking peptide - Protein Information**Name SARS1 ([HGNC:10537](#))

Synonyms SARS, SERS

**Function**

Catalyzes the attachment of serine to tRNA(Ser) in a two-step reaction: serine is first activated by ATP to form Ser-AMP and then transferred to the acceptor end of tRNA(Ser) (PubMed: [22353712](http://www.uniprot.org/citations/22353712), PubMed: [24095058](http://www.uniprot.org/citations/24095058), PubMed: [26433229](http://www.uniprot.org/citations/26433229), PubMed: [28236339](http://www.uniprot.org/citations/28236339), PubMed: [34570399](http://www.uniprot.org/citations/34570399), PubMed: [36041817](http://www.uniprot.org/citations/36041817), PubMed: [9431993](http://www.uniprot.org/citations/9431993)). Is probably also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec) (PubMed: [26433229](http://www.uniprot.org/citations/26433229), PubMed: [28236339](http://www.uniprot.org/citations/28236339), PubMed: [34570399](http://www.uniprot.org/citations/34570399), PubMed: [9431993](http://www.uniprot.org/citations/9431993)). In the nucleus,

binds to the VEGFA core promoter and prevents MYC binding and transcriptional activation by MYC (PubMed:<a href="http://www.uniprot.org/citations/24940000" target="\_blank">24940000</a>). Recruits SIRT2 to the VEGFA promoter, promoting deacetylation of histone H4 at 'Lys- 16' (H4K16). Thereby, inhibits the production of VEGFA and sprouting angiogenesis mediated by VEGFA (PubMed:<a href="http://www.uniprot.org/citations/19423847" target="\_blank">19423847</a>, PubMed:<a href="http://www.uniprot.org/citations/19423848" target="\_blank">19423848</a>, PubMed:<a href="http://www.uniprot.org/citations/24940000" target="\_blank">24940000</a>).

#### **Cellular Location**

Cytoplasm. Nucleus Note=Predominantly cytoplasmic, but a minor proportion is also found in the nucleus.

#### **Tissue Location**

Brain..

### **SARS Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **SARS Antibody (N-term) Blocking peptide - Images**

### **SARS Antibody (N-term) Blocking peptide - Background**

This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts. Multiple alternatively spliced transcript variants have been described but the biological validity of all variants is unknown. [provided by RefSeq].

### **SARS Antibody (N-term) Blocking peptide - References**

Fontaine-Bisson, B., et al. Diabetologia 53(10):2155-2162(2010) Herzog, W., et al. Circ. Res. 104(11):1260-1266(2009) Matsuoka, S., et al. Science 316(5828):1160-1166(2007) Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007) Oh, J.H., et al. Mamm. Genome 16(12):942-954(2005)